Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new chapter in Big Pharma’s billion-dollar war on obesity, as Novo Nordisk and Eli Lilly battle it out over the latest blockbuster drugs.
New Oral Weight Loss Drug Cuts Body Weight by 13% in Just 12 Weeks
Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued weight loss. While well-tolerated, further long-term studies are needed to evaluate its safety and efficacy.
Experimental Weight Loss Drug Beat Ozempic and Wegovy in Early Trial
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.
13% weight loss in 3 months! Obesity pill amycretin shows promise of replacing Ozempic injections
A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those struggling with obesity sitting up and taking notice.
GLP-1 hybrid drug being tested as weight-loss aid
The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.
Wegovy makers say new amycretin weight-loss pill even more effective
Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early trial results.
Weight loss drug challenges Ozempic’s supremacy as subjects lose 13% of body weight
Ozempic might soon have some competition as a new drug trial showed that participants lost 13% of their body weight through a once-a-day tablet. Though somewhat controversial, Ozempic and drugs like it have taken the world by storm as everyone from celebrities to everyday joes are hopping on the health trend.
Early trial shows success for daily weight loss pill: 3 things to know
The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill. Novo Nordisk released data Wednesday showing that patients taking its new medication,
‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
Medical News Today7d
Experimental amycretin pill leads to 13% weight loss in 3 months, Novo Nordisk says
Share on Pinterest Novo Nordisk’s new weight loss pill, amycretin, has had promising results in an early clinical trial. Image credit: SERGEI GAPON/Getty Images. Amycretin, a new weight ...
Fortune8d
Ozempic maker has developed a pill that can cause weight loss of up to 13% in three months
The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to results of a Phase 1 trial. The pill isn’t Ozempic—it’s called ...
Medscape7d
'Remarkable' Weight Loss Seen With Novel Oral Combination That Is Safe and Tolerable in Phase 1 Study
Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.